Introduction: why a supplement on taxanes?

Abstract

The study of paclitaxel (initially known as taxol, which is now the trademark) from its isolation to use in clinical trials is an important chapter in the development of anticancer drugs, going back nearly to the inception of the Chemotherapy Program of the National Cancer Institute (NCI). Thus, it is intimately tied to major aspects of drug development for… (More)
DOI: 10.1097/CAD.0000000000000078

Topics

Cite this paper

@article{Muggia2014IntroductionWA, title={Introduction: why a supplement on taxanes?}, author={Franco M. Muggia}, journal={Anti-cancer drugs}, year={2014}, volume={25 5}, pages={481} }